Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A

@article{Strick2010AlterationsIG,
  title={Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A},
  author={Christine A. Strick and Larry C. James and Carol B. Fox and Thomas Francis Seeger and Frank S. Menniti and Christopher J. Schmidt},
  journal={Neuropharmacology},
  year={2010},
  volume={58},
  pages={444-451}
}
PDE10A is a member of the phosphodiesterase superfamily highly enriched within medium spiny neurons (MSN) in mammalian striatum. We have used inhibitors of PDE10A and quantitative measures of mRNA to demonstrate that PDE10A controls striatal gene expression by regulating MSN cyclic nucleotide signaling pathways. Acute treatment with PDE10A inhibitors produces rapid and transient transcription of the immediate early gene cfos in rat striatum. Although inhibition of PDE10A causes accumulation of… Expand
Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating
TLDR
These findings indicate that TP-10 cannot block dopamine agonist-induced deficits in PPI in the presence of D1 activation and suggest that the effect of PDE10A inhibition on D1 signaling may be counterproductive in some models of antipsychotic activity. Expand
Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.
TLDR
The roles and therapeutic potential of non-selective and selective PDE inhibitors on neural processing in fronto-striatal circuits in normal animals and models of DOPA-induced dyskinesias associated with PD are explored. Expand
Phosphodiesterase 10A in the Rat Pineal Gland: Localization, Daily and Seasonal Regulation of Expression and Influence on Signal Transduction
TLDR
The findings of this study suggest that Pde10a expression is under circadian and seasonal regulation and plays a modulatory role in pineal signal transduction and gene expression. Expand
Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy
TLDR
A radiolabeled PDE10A inhibitor, [(3)H]BMS-843496, is characterized and an ex vivo Pde10 binding autoradiographic assay is developed to explore the relationship between PDE 10 binding site occupancy and the observed biochemical and behavioral effects of PDE20 inhibitors in mice. Expand
Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications
TLDR
The behavioral effects of the selective PDE10A inhibitor MP-10 are compared to those of the clinical standard D₂ antagonist risperidone in rhesus monkeys using a standardized motor disability scale for parkinsonian primates and a newly designed "Drug Effects on Nervous System" scale to assess non-motor effects. Expand
PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?
TLDR
The data on PDE10A inhibition is reviewed as a step toward back-translating the limited antipsychotic efficacy of PDE 10A inhibitors, hopefully to inform new efforts to develop better therapeutics to treat psychosis and schizophrenia. Expand
Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease
TLDR
It is noteworthy that PDE10A inhibition in the R6/2 mice reducesstriatal pathology, consistent with the localization of the enzyme in medium spiny neurons, and also cortical pathology and the formation of neuronal nuclear inclusions, which suggest that striatal pathology may be a primary driver of these secondary pathological events. Expand
Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition.
TLDR
This review will summarize the literature on cyclic nucleotide signaling in the striatum with a particular focus on the impact of cAMP and cGMP on the membrane excitability of striatal medium-sized spiny output neurons (MSNs). Expand
Targeting phosphodiesterase type 4 for improving cognitive fronto-striatal functioning: a translational approach
TLDR
Increased understanding of the subcellular localization and unraveling of the signalosome concept of PDEs including their function and dysfunction in the fronto-striatal circuits will contribute to the design of new selective inhibitors and enhance the potential of Pde inhibitors as therapeutics in fronto’s Striatal circuits. Expand
PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways
TLDR
It is concluded that PDE10AIs stimulate or inhibit motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis
TLDR
The results indicate that PDE10A regulates the activation of striatal medium spiny neurons through effects on cAMP- and cGMP-dependent signaling cascades and demonstrate that papaverine has efficacy in behavioral models predictive of antipsychotic activity. Expand
Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum
TLDR
The roles of PDE4 and PDE10A in dopaminergic neurotransmission in mouse striatum are dissected and the importance of individual brain-enriched cyclic-nucleotide PDE isoforms as therapeutic targets for neuropsychiatric and neurodegenerative disorders affecting dopamine neurotransmission is underscored. Expand
Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation
TLDR
Findings indicate that inhibition of striatal PDE10A activity increases the responsiveness of MSNs to depolarizing stimuli, and support further investigation of selective targeting of PDE signaling pathways in MSN subpopulations. Expand
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function
TLDR
The findings suggest that PDE10A is involved in regulating striatal output, possibly by reducing the sensitivity of medium spiny neurons to glutamatergic excitation, and presents a novel treatment for psychosis. Expand
Immunohistochemical localization of PDE10A in the rat brain
TLDR
Data suggest a role for PDE10A in regulating activity within both the striatonigral and striatopallidal pathways, and a second, distinct function for the enzyme in these regions. Expand
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
TLDR
The studies indicate that PDE 10A is associated with post-synaptic membranes of the medium spiny neurons, suggesting that the specialized compartmentation of PDE10A enables the regulation of intracellular signaling from glutamatergic and dopaminergic inputs to these neurons. Expand
Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A.
TLDR
Findings indicate that PDE10A functions in these tissues, and its presence in the neurons of the striatum and the olfactory tubercle regions of the brain is indicated. Expand
Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species
  • D. Stephenson, T. Coskran, +6 authors D. Morton
  • Biology, Medicine
  • The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • 2009
TLDR
It is suggested that PDE2A is evolutionarily conserved across mammalian species and support the hypothesis that the enzyme plays a fundamental role in signal transduction. Expand
Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia
TLDR
The discovery of a new class of PDE10A inhibitors exemplified by TP-10 (2-{4-[-pyridin-4-yl-1-(2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline succinic acid), an agent with greatly improved potency, selectivity, and pharmaceutical properties is described. Expand
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
TLDR
The differential effects of dopamine on striatonigral and striatopallidal neurons are mediated by their specific expression of D1 and D2 dopamine receptor subtypes, respectively. Expand
...
1
2
3
4
5
...